2 National Melanoma Conference 10 & 11 October 2014, Rendezvous Hotel, Perth
2nd National Melanoma Conference 10 & 11 October 2014, Rendezvous Hotel, Perth Thursday, 9 October 2014 12.00pm – 5.00pm 5.30pm – 7.30pm ANZMTG AGM + ASM Harry Perkins Institute of Medical Research Room: G24 Welcome Reception Harry Perkins Institute of Medical Research Room: Leedman’s Leap Friday, 10 October 2014 8.00am – 9.00am 9.00am – 9.15am 9.15am – 10.35am 9.15am 9.45am 10.15am Registration Opens Rendezvous Hotel, Grand Ballroom East Welcome and Opening Address Ms Lisa Scaffidi, The Right Honourable the Lord Mayor of Perth SESSION ONE: Combination Therapies and Molecular Markers Session Chair: Professor Peter Leedman Convergent de-differentiation during intra-patient evolution in therapy naïve melanoma Professor Mark Shackleton Peter MacCallum Cancer Centre, Vic Inability to cell cycle arrest in response ATM checkpoint signaling is a common feature of melanomas Professor Brian Gabrielli UQ/Diamantina Institute, Qld Targeting Rab27a to suppress melanoma proliferation and invasion Dr Kim Beaumont Centenary Institute, NSW 10.35am – 11.00am Morning Tea – Grand Ballroom West 11.00am – 11.45am SESSION TWO: Grand Ballroom East: Insights into Melanoma Biomarkers Session Chair: Professor Mark Shackleton Keynote Lecture Understanding the biology of melanocytes and melanoma cells to develop new strategies for therapy Professor Meenhard Herlyn Molecular and Cellular Oncogenesis; Director for Translational Research, Wistar Institute Cancer Centre, Phil. USA Lunch + Poster Session – Grand Ballroom West 11.00am 11.45am – 12.45pm 12.45pm – 2.15pm 12.45pm 1.15pm 1.45pm SESSION THREE: Grand Ballroom East: Epidemiology and Early Diagnosis Session Chair: Professor Charles Balch Professor Graham Mann Chair, University of Sydney Cancer Research Network Co-Director, Centre for Cancer Research | Westmead Millennium Institute Research Director | Melanoma Institute Australia Diagnosis, initial treatment and supportive care needs of adults with localised melanoma in Queensland: The Primary Melanoma Project Professor Adele Green QIMR Berghofer Medical Research Institute Qld The genetic architecture of melanoma susceptibility Professor Nick Hayward QIMR Berghofer Medical Research Institute Qld 2.15pm – 3.10pm SESSION FOUR: Signalling pathways, cellular resistance & novel treatments 2.15pm Dual Targeting the MAPK/ERK and CDK4 Pathways in Melanoma Induces Sustained Tumor Regression Page 1 of 3 2.35pm 2.50pm 3.10pm - 3.40pm 3.40pm – 4.40pm 3.40pm 3.55pm 4.10pm 4.25pm 4.40pm 6.00pm - 7.00pm 7.00pm – 11.30pm Dr Karen Sheppard Peter MacCallum Cancer Centre A systems biology approach identifies synergistic drug-immunotherapy combinations Dr Joost Lesterhuis University of Western Australia Melanoma cells in G1 phase escape proteasome inhibitor cytotoxicity A/Prof Nikolas Haass University Of Queensland Diamantina Institute/Translational Research Institute Afternoon Tea – Grand Ballroom West SESSION FIVE: Grand Ballroom East: SKMRC Discovery Grant Recipients Session Chair: Professor Adele Green MicroRNA-7-5p suppresses melanoma metastasis by inhibiting insulin receptor substrate-2 expression and NF-B signalling Dr Keith Giles New York University, NY, USA Vemurafenib treatment selects for melanoma cells expressing the ABCB5-transporter Dr Elin Gray Edith Cowan University, WA A novel immune component of the susceptibility formula for melanoma Dr Prue Hart Telethon Kids Institute, WA Genetic Predictors of Melanoma Outcomes Professor Grant Morahan UWA/Perkins Institute, WA Close Wine Tasting - Guided Session Conference Dinner – Mentelle Room, Rendezvous Grand Hotel 7pm Pre dinner drinks Saturday, 11 October 2014 7.30am – 8.00am 7.30am - 10.00am 8.00am – 9.00am 9.00am – 1000am 10.15am – 12.40pm 10.15am 11.00am 11.25am 11.50am Registration Melanoma Consumer Forum - Supported by MelanomaWA Rendezvous Hotel, Preston Room (B&C) Session Chair: Dr Mark Lee Professor Charles Balch, Professor Michael Millward, Ms Karen Anderson Workshop Session and Panel Discussion SESSION SIX: Surgical and Clinical Advances in Melanoma Session Chair: Professor John Thompson Keynote Lecture Staging and Surgical Management of Melanoma Professor Charles Balch Professor of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center The important, continuing roles of surgery and loco-regional treatments in melanoma management in the era of more effective systemic therapies Professor John Thompson Melanoma Institute Australia, NSW Paediatric Melanoma in Western Australia Dr Mark Lee UWA/SJOGH, WA Surgical and Clinical Advances in Melanoma Professor Michael Millward UWA/SCGH, WA Page 2 of 3 12.15pm 12.40pm – 1.30pm 1.30pm – 2.45pm 1.30pm 2.15pm 2.30pm 2.45pm - 3.15pm 3.15pm – 4.30 pm 3.15pm 3.30pm 3.45pm 4.00pm 4.15pm 4.30pm Melanoma Biomarkers in the Molecular era Professor Richard Scolyer Melanoma Institute Australia, NSW Lunch – Grand Ballroom West SESSION SEVEN: Grand Ballroom East: Session Chair: Professor Richard Scolyer Keynote Lecture Primary overall survival (OS) from OPTiM, a randomised phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma Professor Robert Andtbacka University of Utah, USA Session Sponsored by Amgen Australia PET CT in Melanoma Dr Louise Emmett St Vincent’s Hospital, NSW Emerging Radiotherapy Techniques in The Management of Melanoma Dr Bryan Burmeister Princess Alexandra Hospital, Qld Afternoon Tea ANZMTG Trial update Session Chair: Professor Bryan Burmeister ANZMTG 01.14 ABC Nivo trial - A phase II study of nivolumab and nivolumab in combination with ipilimumab in patients with melanoma brain metastases. Presented by Associate Professor Georgina Long ANZMTG 02.14 CombiRT trial - An open-label, single-arm, phase I/II, multicentre study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with unresectable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation- positive cutaneous melanoma. Presented by Dr Tim Wang ANZMTG 01.12 EAGLE FM trial – Evaluation of Groin Lymphadenectomy Extent For metastatic Melanoma; A randomised phase III trial investigating Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes with no evidence of pelvic disease on PET/CT Scan. Presented by Libby Paton on behalf of Associate Professor Andrew Spillane ANZMTG 03.12 Melanoma Margins Trial (MelMarT) Trial: A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. Presented by Professor Michael Henderson on behalf of Dr Marc Moncrieff ANZMTG 02.12 Radiotherapy or Imiquimod observed with Confocal microscopy in lentigo mALigna (RADICAL) Trial; A Phase III trial of imiquimod vs radiotherapy for lentigo maligna mapped with reflectance confocal microscopy. Presented by Associate Professor Gerald Fogarty on behalf of Dr Pascale Guitera Conference wrap up and Close Page 3 of 3
© Copyright 2024